AUTHORS
Daniel Landsburg, MD, Natasha Shamas2, Anthony Masaquel, PhD, MPH3, Lourenia Cassoli, MD, MSc4, Adriano Sa, MD, MSc5, Sai Li6, Yong Mun, PhD7, Evelyn M. Flahavan, PhD8, Laura Perez9, Carolina Reyes, PhD10, Patrick M Reagan, MD11
AFFILIATIONS
1 University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 Genentech, Inc., South San Francisco, California, United States
3 Genentech, Inc., South San Francisco, California, United States
4 Genentech, Inc., South San Francisco, California, United States
5 F. Hoffmann-La Roche Ltd, Basel, Switzerland
6 F. Hoffmann-La Roche Ltd, Basel, Switzerland
7 Genentech, Inc., South San Francisco, California, United States
8 Genentech, Inc., South San Francisco, California, United States
9 F. Hoffmann-La Roche Ltd, Basel, Switzerland
10 Genentech, Inc., South San Francisco, California, United States
11 University of Rochester, Rochester, New York, United States
ABSTRACT
Background: The Phase III POLARIX study (NCT03274492) reported improved progression-free survival (PFS) of polatuzumab vedotin (Pola) in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (Pola-R-CHP) compared with rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) in patients with previously untreated, intermediate- or high-risk DLBCL (Tilly et al. NEJM 2022). Consequently, Pola-R-CHP has become a standard of care for first-line (1L) DLBCL globally.
Real-world (RW) evidence on the use of Pola-R-CHP in the US has been limited and has primarily included patients treated at academic cancer centers, demonstrating that Pola-R-CHP has a manageable safety profile and is effective in patients with previously untreated DLBCL (Iyengar et al. ASH 2024; Thiruvengadam et al. EHA 2025; Thiruvengadam et al. ICML 2025). Data from broader clinical practice, including community settings, is needed to confirm these findings in a larger, more diverse patient population. This study aimed to describe patient characteristics, treatment patterns, and effectiveness of Pola-R-CHP in patients with previously untreated DLBCL in the US, including representation of patients from community cancer centers.
Methods: This study used the electronic health record-derived, US nationwide, de-identified real-world Flatiron Health Research Database. Patients diagnosed with DLBCL who had initiated 1L Pola-R-CHP between January 1, 2023 and April 30, 2026, were included. Multiple imputation was applied to account for missing clinical data that comprise the International Prognostic Index (IPI) score. Effectiveness was assessed using real-world progression-free survival (rwPFS) and overall survival (OS). Disease progression was defined using the earliest evidence from radiology/pathology reports, physical exams, or other clinical evidence. Summary statistics and Kaplan-Meier estimates were utilized.
Results: The study included 389 patients treated with 1L Pola-R-CHP. Median age was 69 years (range 21–85), 13% (n=49) were ≥ 80 years, 42% (n=164) were female, 83% (n=271) were White. Complete IPI information was documented in 17% (n=66) patients. Based on imputation methods, 17% (n=68) had an IPI score 0-1, 35% (n=135) had an IPI score of 2, and 48% (n=186) had an IPI score 3-5 . Most patients (88%; n=341) had DLBCL not otherwise specified and 12% (n=46) had DLBCL transformed from a prior indolent lymphoma. Of those with available data, double-hit lymphoma and double-expressor lymphoma were identified in 5% (n=19) and 21% (n=80) of patients, respectively. The proportion of patients that had a cell of origin of germinal center B-cell (GCB) and non-GCB were similar 39% (n=151) and 42% (n=164), respectively. Overall, 78% (N=286) of patients received care from a community setting and 33% (n=118) fell into the lowest two socioeconomic status score (SES) quintiles.
Median follow-up was 12.9 months. Regarding disposition, 78% (n=305) of patients were in ongoing follow-up with no documented second line (2L) therapy, 14% (n=55) had initiated 2L therapy, and 8% (n=29) had died with no documented 2L therapy. The median number of cycles for Pola-R-CHP was 6 (range 1–12). A total of 2% (N=7) of patients received a Pola-containing regimen in a subsequent line. Median rwPFS and OS were not reached. Event-free 12-month survival rates for rwPFS and OS were 87% (95% confidence interval [CI]: 82%, 91%) and 87% (95% CI: 84%, 91%), respectively.
Subgroup analyses revealed 12-month rwPFS for GCB vs non-GCB was 89% (95% CI: 83%, 95%) and 85% (95% CI: 78%, 92%), respectively. Additionally, 12-month rwPFS rates were also consistent across SES quintiles 1–2 (87%; 95% CI: 79%, 96%) vs 3–5 (88%; 95% CI: 83%. 93%). The 12-month rwPFS rates were numerically higher for patients with IPI 0-1 (96.1%; 95% CI: 91.0%, 100%) and similar for IPI 2 (82.7%; 95% CI 74.8%, 91.4%) and IPI 3-5 (86.1%, 79.9%, 92.7%).
Conclusions: In this RW cohort of patients with DLBCL receiving 1L Pola-R-CHP, which included 17% of patients with IPI <2, the 12-month rwPFS rate closely aligned with the landmark POLARIX results. These updated analyses, with longer follow-up, contribute to the notable evidence suggesting that the effectiveness and durability of Pola-R-CHP in routine clinical practice across diverse patient subgroups is consistent with that observed in POLARIX.
DISCLOSURES
Daniel Landsburg, MD: Novartis, ADC Therapeutics - Honoraria; Novartis, ADC Therapeutics - Research Funding; AbbVie - Consultancy (Includes expert testimony); Abbvie, Novartis, ADC Therapeutics, Natera, Ipsen, Kite, Regeneron - Consultancy (Includes expert testimony)